Literature DB >> 35709495

The Kinetics and (Dys)kinetics of Cancer Chronotherapy.

Jeffrey M Field1, Amita Sehgal2.   

Abstract

Circadian rhythms are the daily cycles that time almost all aspects of physiology, but treatments of the clock or by the clock are rarely tested in the clinic. We develop a framework for identifying interventions that may benefit from administration at the appropriate time of day (chronotherapy). Typically, pharmacokinetics is an important consideration for chronotherapy, with short half-life drugs deemed optimal for such treatments. However, recent data suggest long-lived antibodies can show time-of-day specific effects. Examples include both tumor-targeted antibodies as well as immunotherapies with antibodies that activate T cells. Clues to the immunotherapy mechanism come from animal vaccination studies, which demonstrate circadian responses of T cells to a single dose that leads to long-lasting T-cell activation. Conversely, some studies have challenged the efficacy of chronotherapy, underscoring the need to rigorously investigate its application for each drug and tumor type. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35709495      PMCID: PMC9256782          DOI: 10.1158/0008-5472.CAN-21-3799

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  9 in total

Review 1.  Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy.

Authors:  Robert Dallmann; Alper Okyar; Francis Lévi
Journal:  Trends Mol Med       Date:  2016-04-05       Impact factor: 11.951

2.  The circadian clock of CD8 T cells modulates their early response to vaccination and the rhythmicity of related signaling pathways.

Authors:  Chloé C Nobis; Geneviève Dubeau Laramée; Laura Kervezee; Dave Maurice De Sousa; Nathalie Labrecque; Nicolas Cermakian
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-16       Impact factor: 11.205

Review 3.  Clocks, cancer, and chronochemotherapy.

Authors:  Aziz Sancar; Russell N Van Gelder
Journal:  Science       Date:  2021-01-01       Impact factor: 47.728

Review 4.  Medicine in the Fourth Dimension.

Authors:  Christopher R Cederroth; Urs Albrecht; Joseph Bass; Steven A Brown; Jonas Dyhrfjeld-Johnsen; Frederic Gachon; Carla B Green; Michael H Hastings; Charlotte Helfrich-Förster; John B Hogenesch; Francis Lévi; Andrew Loudon; Gabriella B Lundkvist; Johanna H Meijer; Michael Rosbash; Joseph S Takahashi; Michael Young; Barbara Canlon
Journal:  Cell Metab       Date:  2019-08-06       Impact factor: 27.287

5.  Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer.

Authors:  Jiao Wang; Qiong Huang; Xingbin Hu; Shuyi Zhang; Yu Jiang; Guangyu Yao; Kongzhen Hu; Xin Xu; Bishan Liang; Qijing Wu; Zhenfeng Ma; Yawen Wang; Chunlin Wang; Zhenzhen Wu; Xiaoxiang Rong; Wangjun Liao; Min Shi
Journal:  Cancer Res       Date:  2022-04-15       Impact factor: 12.701

6.  Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.

Authors:  David C Qian; Troy Kleber; Brianna Brammer; Karen M Xu; Jeffrey M Switchenko; James R Janopaul-Naylor; Jim Zhong; Melinda L Yushak; R Donald Harvey; Chrystal M Paulos; David H Lawson; Mohammad K Khan; Ragini R Kudchadkar; Zachary S Buchwald
Journal:  Lancet Oncol       Date:  2021-11-12       Impact factor: 41.316

7.  Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.

Authors:  Pasquale F Innominato; Annabelle Ballesta; Qi Huang; Christian Focan; Philippe Chollet; Abdoulaye Karaboué; Sylvie Giacchetti; Mohamed Bouchahda; René Adam; Carlo Garufi; Francis A Lévi
Journal:  Cancer Med       Date:  2020-04-22       Impact factor: 4.452

8.  Time-of-day specificity of anticancer drugs may be mediated by circadian regulation of the cell cycle.

Authors:  Yool Lee; Shi Yi Fong; Joy Shon; Shirley L Zhang; Rebekah Brooks; Nicholas F Lahens; Dechun Chen; Chi Van Dang; Jeffrey M Field; Amita Sehgal
Journal:  Sci Adv       Date:  2021-02-12       Impact factor: 14.136

9.  Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer.

Authors:  Abdoulaye Karaboué; Thierry Collon; Ida Pavese; Viviane Bodiguel; Joel Cucherousset; Elda Zakine; Pasquale F Innominato; Mohamed Bouchahda; René Adam; Francis Lévi
Journal:  Cancers (Basel)       Date:  2022-02-11       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.